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Conclusion: Based on the modest variations in RR across the 
large spread in parameter values, the treatment modalities 
are not expected to have very different SC risk profiles with 
respect to these organs. The α value had the strongest 
influence on the RR and may change the RR in favour of one 
technique instead of another (particle vs photons). 
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Purpose or Objective: Treatment plans for intensity-
modulated proton therapy (IMPT) can be robustly optimized 
by performing ‘minimax’ worst-case optimization, in which a 
limited number of error scenarios is included in the 
optimization. However, it is currently unknown which error 
scenarios should be included for given population-based 
distributions of setup errors and range errors. The aim of this 
study is to derive a 'robustness recipe' describing the setup 
robustness (SR; in mm) and range robustness (RR; in %) 
settings (i.e. the absolute error values of the included 
scenarios) that should be applied in minimax robust IMPT 
optimization to ensure adequate CTV coverage in 
oropharyngeal cancer patients, for given Gaussian 
distributions of systematic and random setup errors and 
range errors (characterized by standard deviations Σ, σ and 
ρ, respectively). 
 
Material and Methods: In this study contoured CT scans of 6 
unilateral and 6 bilateral oropharyngeal cancer patients were 
used. Robustness recipes were obtained by: 1) generating 
treatment plans with varying robustness settings SR and RR, 
2) performing comprehensive robustness analyses for these 
plans using different combinations of systematic and random 
setup errors and range errors (i.e. different values of Σ, σ 
and ρ), and 3) determining the maximum errors for which 
certain SR and RR settings still resulted in adequate CTV 
coverage. IMPT plans were considered adequately robust if at 
least 98% CTV coverage (V95% ≥ 98%) was achieved in 98% of 
the simulated fractionated treatments. Robustness analyses 
were performed using Polynomial Chaos methods, which 
allow for fast and accurate simulation of the expected dose 
in fractionated IMPT treatments for given error distributions. 
Separate recipes were derived for the unilateral and bilateral 
cases using one patient from each group. The robustness 
recipes were validated using all 12 patients, in which 2 plans 
were generated for each patient corresponding to Σ = σ = 1.5 
mm and ρ = 0% and 2%. 
 
Results: The robustness recipes are depicted in Figure 1. We 
found that 1) systematic setup errors require larger SR than 
random setup errors, 2) bilateral cases are intrinsically more 
robust than unilateral cases, 3) the required RR only depends 
on ρ, and 4) the required SR can be fitted by second order 
polynomials in Σ and σ. The formulas for the robustness 
recipes are: SR = −0.15Σ² + 0.27σ² + 1.85Σ − 0.06σ + 1.22 and 
RR = 3% for ρ = 1% and 2% for unilateral cases, and SR = 
−0.07Σ² + 0.19σ² + 1.34Σ − 0.07σ + 1.17 and RR = 3% and 4% 
for ρ = 1% and 2%, respectively, for bilateral cases. The 
recipe validation resulted in 22 plans being adequately 
robust, while for the remaining two plans CTV coverage was 
adequate in 97.8% and 97.9% of the simulated fractionated 
treatments. 
 
 
 
Conclusion: Robustness recipes were derived that can be 
used in minimax robust optimization of IMPT treatment plans 
to ensure adequate CTV coverage for oropharyngeal cancer 
patients. 
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Purpose or Objective: Stereotactic body radiotherapy (SBRT) 
is increasingly used to treat low and intermediate stage 
prostate cancer (PC). In our institution, SBRT is delivered in 
4-5 fractions of high dose using the CyberKnife system with 
marker-based tracking. Tracking accurately aligns the 
treatment beams to the prostate just prior and during the 
treatment fraction. However, surrounding organs at risks 
(OARs) may move relative to the prostate, causing the OAR 
dose to deviate from what was planned. The aim of this work 
is to quantify the daily dose to OARs in SBRT for PC, and 
compare it to the planned dose. 
 
Material and Methods: For 9 patients, four to five repeat CT 
scans were acquired prior to each daily SBRT fraction and 
were analyzed. The bladder, rectum, anus, and urethra were 
contoured in the planning and repeat CTs. The urethra was 
divided in three parts: the cranial and the caudal part of the 
urethra prostatica (UP) and the membranous urethra (MU, 2 
cm caudal to the prostate). The repeat CTs were aligned to 
the planning CT based on the four implanted markers. 
Subsequently, the planned dose distribution was projected on 
the aligned repeat CTs. For each patient, dose-volume 
parameters of the OARs were recorded, averaged over the 4-
5 repeat CTs and compared to planning. 
 
Results: The greatest deviation between the delivered and 
planned dose was seen for the MU. The planned mean dose of 
24.0 Gy was exceeded in the repeat CTs by on average 
59±17% (1 SD) and the D5% was increased by 7±3%, from 38.7 
to 41.6 Gy (Fig. 1a). For the mean dose of the caudal and 
cranial UP the deviation from planning was limited: 1±1% and 
5±5% respectively. The planned mean and V1cc (dose allowed 
to 1cc of the organ) rectum dose, 10.9 and 32.8 Gy 
respectively, was on average 5±5% and 12±11% higher in the 
repeat CTs (Fig. 1b). The mean dose of the anus increased as 
well, with 15±24% from 8.7 to 9.8 Gy. The planned V1cc 
bladder dose (40.2 Gy) was reproducible in the repeat CTs 
ESTRO 35 2016                                                                                                                                                    S267 
______________________________________________________________________________________________________ 
(difference: 1±1%). The planned mean bladder dose (18.4 Gy) 
was slightly reduced in the repeat CTs (-6±7%). 
 
 
 
Conclusion: For the membranous urethra, rectum, and anus, 
the dose in the repeat CTs was higher than was planned. This 
warrants future research investigating whether increased 
dose leads to increased incidence of side effects and whether 
dose increases should be mitigated by treatment adaptations. 
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Purpose or Objective: Endpoints for this ethically approved 
clinical study:  
- Assess the feasibility of planning SABR for low-intermediate 
risk prostate cancer using flattening filter free volumetric arc 
therapy.  
- Assess safety of treatment delivery by recording RTOG 
scoring criteria of acute gastro-intestinal (GI) and genito-
urinary (GU) toxicity. 
 
Material and Methods: 25 patients were included, each has 
18 week toxicity data.  
Inclusion criteria: 
Written informed consent, 18 - 80 years, T1-T2 stage, WHO 
performance status ≤ 2. Initial PSA ≤ 20 ng/ml. Gleason score 
≤7 with histologically-proven prostate adenocarcinoma. No 
pathologic lymph nodes on CT/ MRI scans and no distant 
metastases. No previous prostate surgery, including 
transurethral resection of the prostate no TURP in past 6 
months. No previous active malignancy within the last 10 
years.  
A prescription dose of 35Gy in 5 fractions was treated 
alternate days. This was planned using Rapidarc VMAT 
planning on Varian Eclipse (V.10), treated using a Varian 
Truebeam STX.  
A clinically acceptable plan was determined by assessing the 
planned dose to GTV/PTV criteria and achieving dose 
constraints (table 1).  
 
GI, GU and skin toxicity was scored using Radiation therapy 
oncology group (RTOG) criteria. Baseline data was recorded 
before treatment commenced (baseline), week 4 and week 
18. 
 
Results: Results include first 25 patients.  
Age range was 52-78, median 70, initial PSA median 4.3-29.2, 
median 10.8ng/ml. All patients were successfully planned 
and treated with VMAT-FFF with plans being deemed 
clinically acceptable for 100% of patients.  
GU and GI toxicity at baseline, week 4 and week 18 is 
detailed for each grade below, respectively.  
GU toxicity: 
Grade 0 - 44%, 12%, 48%  
Grade 1 - 52%, 56%, 48%  
Grade 2 – 4%, 28%, 4%  
Grade 3 – 0%, 4%, 0%  
For GU toxicity, a statistically significant increase in toxicity 
was observed from baseline to week 4 (p=<0.01) and a 
significant reduction from week 4 to week 18 (p=<0.01). No 
significant difference was observed between baseline and 
week 18, with toxicity reducing to similar levels as baseline.  
GI toxicity (baseline, week 4, week 18): 
Grade 0 – 96%, 52%, 72%  
Grade 1 – 4%, 40%, 28%  
Grade 2 – 0%, 8%, 0%  
Grade 3 – 0%,0%, 0%  
GI toxicity significantly increased from baseline to week 4 
(p=<0.01). From week 4 to week 18, toxicity had reduced 
(p=<0.05). A significant difference was observed between 
baseline and week 18 (p=<0.05) with toxicity having reduced, 
but not having returned to baseline grade. 
 
Conclusion: Highly conformal plans were created for all 
patients. Toxicity was acceptable throughout, with toxicity 
at week 18 reducing to that of baseline for GU toxicity, and 
reducing significantly for GI toxicity. 1 patient experienced 
grade 3 GU toxicity at week 4, this resolved by week 10. 
Longer follow-up is required to assess late outcomes. 
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Purpose or Objective: To investigate the feasibility of single 
fraction High Dose Rate (HDR) brachytherapy (BT) as 
monotherapy for low risk prostate cancer. 
 
Material and Methods: CT scans of 30 patients were selected 
from our prostate HDR database. Patients were divided in 
groups based on prostate volume (< 40cc, 40-70cc and >70cc) 
and the number of needles used (13-16 and 17-22). The 
